Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial
Stocks

Portfolio: Exiting Aarti Drugs and GSFC From Momentum

SquareAd.png

Markets have been seeing red continuously. Nifty is down by 2.6% in last five trading sessions. We got rid of two positions from momentum portfolio as they were breaking down. On 23-Sep we added Aarti drugs to our momentum portfolio. Fundamentally the company had decent results. Revenue was up by 2.17% and PAT was remarkably up by 37% YoY. Aarti Drugs has generated 80.68% of revenue from speciality chemicals, 13.87% from pharmaceuticals and and rest from home and personal care chemicals. The company has recently . . .

Like our content? Join Capitalmind Premium.

  • Equity, fixed income, macro and personal finance research
  • Model equity and fixed-income portfolios
  • Exclusive apps, tutorials, and member community
Subscribe Now Or start with a free-trial